Table 1

Median length of the hazard period and (relative) frequency of the individuals across clinical cohort levels

Lifetime

survival

(n = 287)1

Overall survival

(n = 287)2

Progression-free

survival

(n = 284) 2


Censored

(0.12)

(0.12)

(0.23)

Lifetime

59.2

13.1

6.5

Gender

Male

58.8

(0.63)

13.6

(0.63)

6.6

(0.63)

Female

61.1

(0.37)

12.1

(0.37)

6.4

(0.37)

Race

White

59.7

(0.77)

13.1

(0.77)

6.8

(0.77)

Other

57.7

(0.23)

12.6

(0.23)

5.3

(0.23)

Therapy

CRnoT

57.7

(0.40)

15.7

(0.40)

8.0

(0.34)

R

60.7

(0.35)

12.3

(0.35)

5.3

(0.41)

CRT

53.4

(0.10)

15.4

(0.10)

6.8

(0.10)

Other

64.8

(0.08)

14.2

(0.08)

7.9

(0.08)

None

70.5

(0.07)

2.9

(0.07)

1.4

(0.07)

ProgRec

Yes

57.6

(0.77)

15.1

(0.77)

-

(0.77)

No

64.8

(0.23)

5.9

(0.23)

-

(0.23)


1 expressed in years;

2 expressed in months.

SerĂ£o et al. BMC Medical Genomics 2011 4:49   doi:10.1186/1755-8794-4-49

Open Data